The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Advocates for HIV prevention are calling a newly approved injectable medication a major step in eliminating the spread of the ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

In a major advancement for global HIV prevention, the World Health Organisation (WHO) has officially recommended injectable ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Walgreens Specialty Pharmacy has expanded its limited distribution drug (LDD) network to now include 265 products, placing it ...

The global HIV diagnostics market is expected to grow at a CAGR of ~10% during the forecast period. Rising prevalence of HIV ...

Walgreens Specialty Pharmacy, which earned $25.9 billion last year from U.S. prescription revenue, has expanded its limited distribution drug portfolio to 265 medications, the company said Aug. 19. ...

As international funding rapidly recedes, African countries — among those with the highest new HIV infection rates are ...